CN108714171A - 一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺 - Google Patents
一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺 Download PDFInfo
- Publication number
- CN108714171A CN108714171A CN201810590903.8A CN201810590903A CN108714171A CN 108714171 A CN108714171 A CN 108714171A CN 201810590903 A CN201810590903 A CN 201810590903A CN 108714171 A CN108714171 A CN 108714171A
- Authority
- CN
- China
- Prior art keywords
- fructose
- exocarpium citri
- citri rubrum
- formula
- hours
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930091371 Fructose Natural products 0.000 title claims abstract description 73
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 title claims abstract description 73
- 239000005715 Fructose Substances 0.000 title claims abstract description 73
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical group C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 title claims abstract description 71
- 210000000988 bone and bone Anatomy 0.000 title claims abstract description 35
- 238000005516 engineering process Methods 0.000 title claims abstract description 31
- 238000012545 processing Methods 0.000 title claims abstract description 20
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 235000013402 health food Nutrition 0.000 title claims abstract description 13
- 238000005728 strengthening Methods 0.000 title description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 22
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims description 17
- 239000013078 crystal Substances 0.000 claims description 17
- 230000002829 reductive effect Effects 0.000 claims description 16
- -1 filtering Substances 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 239000007788 liquid Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 235000019441 ethanol Nutrition 0.000 claims description 10
- 239000000706 filtrate Substances 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 238000010025 steaming Methods 0.000 claims description 10
- 238000009835 boiling Methods 0.000 claims description 9
- 229940100688 oral solution Drugs 0.000 claims description 9
- 238000001914 filtration Methods 0.000 claims description 7
- 239000006071 cream Substances 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 238000004064 recycling Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 241000675108 Citrus tangerina Species 0.000 claims 2
- 241001122767 Theaceae Species 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 238000003756 stirring Methods 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 abstract description 43
- 229920002527 Glycogen Polymers 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 21
- 229940096919 glycogen Drugs 0.000 abstract description 21
- 230000006378 damage Effects 0.000 abstract description 16
- 230000003387 muscular Effects 0.000 abstract description 14
- 230000015572 biosynthetic process Effects 0.000 abstract description 11
- 230000033001 locomotion Effects 0.000 abstract description 10
- 238000003786 synthesis reaction Methods 0.000 abstract description 10
- 230000002708 enhancing effect Effects 0.000 abstract description 7
- 230000032683 aging Effects 0.000 abstract description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 5
- 102000008186 Collagen Human genes 0.000 abstract description 4
- 108010035532 Collagen Proteins 0.000 abstract description 4
- 208000029549 Muscle injury Diseases 0.000 abstract description 4
- 229920001436 collagen Polymers 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 4
- 239000013589 supplement Substances 0.000 abstract description 4
- 102000004877 Insulin Human genes 0.000 abstract description 3
- 108090001061 Insulin Proteins 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 229940125396 insulin Drugs 0.000 abstract description 3
- 230000007812 deficiency Effects 0.000 abstract description 2
- 201000010099 disease Diseases 0.000 abstract description 2
- 230000004064 dysfunction Effects 0.000 abstract description 2
- 230000036407 pain Effects 0.000 abstract description 2
- 230000037361 pathway Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 208000000112 Myalgia Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 208000013465 muscle pain Diseases 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 19
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 229920001282 polysaccharide Polymers 0.000 description 10
- 239000005017 polysaccharide Substances 0.000 description 10
- 206010011224 Cough Diseases 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- 150000004676 glycans Chemical class 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 6
- 238000003304 gavage Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- DFPMSGMNTNDNHN-ZPHOTFPESA-N naringin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O[C@H](CO)[C@@H](O)[C@@H]1O DFPMSGMNTNDNHN-ZPHOTFPESA-N 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 210000000107 myocyte Anatomy 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000003505 Myosin Human genes 0.000 description 4
- 108060008487 Myosin Proteins 0.000 description 4
- 229910019142 PO4 Inorganic materials 0.000 description 4
- 206010036790 Productive cough Diseases 0.000 description 4
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 4
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000000354 decomposition reaction Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 230000004118 muscle contraction Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- 239000010452 phosphate Substances 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 229940116269 uric acid Drugs 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 229930003944 flavone Natural products 0.000 description 3
- 235000011949 flavones Nutrition 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002207 metabolite Substances 0.000 description 3
- 210000002997 osteoclast Anatomy 0.000 description 3
- 208000026435 phlegm Diseases 0.000 description 3
- 210000001908 sarcoplasmic reticulum Anatomy 0.000 description 3
- 230000012232 skeletal muscle contraction Effects 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- BGEBZHIAGXMEMV-UHFFFAOYSA-N 5-methoxypsoralen Chemical compound O1C(=O)C=CC2=C1C=C1OC=CC1=C2OC BGEBZHIAGXMEMV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 244000276331 Citrus maxima Species 0.000 description 2
- 235000001759 Citrus maxima Nutrition 0.000 description 2
- 102000003793 Fructokinases Human genes 0.000 description 2
- 108090000156 Fructokinases Proteins 0.000 description 2
- 108010001483 Glycogen Synthase Proteins 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- RPMNUQRUHXIGHK-PYXJVEIZSA-N apigenin 7-O-neohesperidoside Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=C2C(=O)C=C(C=3C=CC(O)=CC=3)OC2=C1 RPMNUQRUHXIGHK-PYXJVEIZSA-N 0.000 description 2
- 229930034861 apigenin-7-O-neohesperidoside Natural products 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229930003935 flavonoid Natural products 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- 235000017173 flavonoids Nutrition 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000034659 glycolysis Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000013067 intermediate product Substances 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- RPMNUQRUHXIGHK-SBDOOABHSA-N rhoifolin Natural products O([C@@H]1[C@@H](O)[C@H](O)[C@H](CO)O[C@H]1Oc1cc(O)c2C(=O)C=C(c3ccc(O)cc3)Oc2c1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](C)O1 RPMNUQRUHXIGHK-SBDOOABHSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 2
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- GMRQFYUYWCNGIN-ZVUFCXRFSA-N 1,25-dihydroxy vitamin D3 Chemical compound C1([C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](CCCC(C)(C)O)C)=CC=C1C[C@@H](O)C[C@H](O)C1=C GMRQFYUYWCNGIN-ZVUFCXRFSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- 239000001606 7-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-5-hydroxy-2-(4-hydroxyphenyl)chroman-4-one Substances 0.000 description 1
- 101710177847 Actin, muscle Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- DBMJZOMNXBSRED-UHFFFAOYSA-N Bergamottin Natural products O1C(=O)C=CC2=C1C=C1OC=CC1=C2OCC=C(C)CCC=C(C)C DBMJZOMNXBSRED-UHFFFAOYSA-N 0.000 description 1
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- MNQZXJOMYWMBOU-VKHMYHEASA-N D-glyceraldehyde Chemical compound OC[C@@H](O)C=O MNQZXJOMYWMBOU-VKHMYHEASA-N 0.000 description 1
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010057178 Osteoarthropathies Diseases 0.000 description 1
- 102000004067 Osteocalcin Human genes 0.000 description 1
- 108090000573 Osteocalcin Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 102000008108 Osteoprotegerin Human genes 0.000 description 1
- 108010035042 Osteoprotegerin Proteins 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 241001523486 Poncirus Species 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003262 anti-osteoporosis Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960002045 bergapten Drugs 0.000 description 1
- KGZDKFWCIPZMRK-UHFFFAOYSA-N bergapten Natural products COC1C2=C(Cc3ccoc13)C=CC(=O)O2 KGZDKFWCIPZMRK-UHFFFAOYSA-N 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 235000020964 calcitriol Nutrition 0.000 description 1
- 239000011612 calcitriol Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 230000004094 calcium homeostasis Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000010523 cascade reaction Methods 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 208000017580 chronic wasting disease Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000004459 forage Substances 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000006749 inflammatory damage Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229930003658 monoterpene Natural products 0.000 description 1
- 150000002773 monoterpene derivatives Chemical class 0.000 description 1
- 235000002577 monoterpenes Nutrition 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 201000006938 muscular dystrophy Diseases 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000010016 myocardial function Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 229930019673 naringin Natural products 0.000 description 1
- 229940052490 naringin Drugs 0.000 description 1
- ARGKVCXINMKCAZ-UZRWAPQLSA-N neohesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@H]3[C@@H]([C@H](O)[C@@H](O)[C@H](C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UZRWAPQLSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- URLKBWYHVLBVBO-UHFFFAOYSA-N p-dimethylbenzene Natural products CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000013001 point bending Methods 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229940106904 rocaltrol Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000004143 urea cycle Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Medical Informatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Zoology (AREA)
- Physiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺运动过量易造成肌肉损伤，疼痛及功能障碍，还容易导致骨折，本发明公开了由果糖与橘红组成一组强骨壮肌增强运动能力的保健食品和药品，包括5个不同剂型的制剂，本发明的特征是由12%果糖与50%橘红组成的组合物，这些组合物对于运动过量，损伤，疾病或者衰老导致的骨生物力学性能下降及肌肉疲劳有预防作用，本配方中的果糖可以使肌肉获得生命必须的能量补充，果糖可以不通过胰岛素途径直接进入肌肉，直接转化为肌糖原，及时补充了肌肉组织细胞因能量缺乏导致的代谢障碍，同时，橘红可以增加骨的生物力学性能，特别是增加骨的胶原蛋白的合成，使骨的弹性载荷明显提升，运动时不容易发生骨折，与果糖合用对强骨壮肌增强运动能力很有效。
Description
技术领域
本发明属于保健食品与药品生产的技术领域，具体涉及一组由果糖、橘红组成的具有增强肌肉增强运动能力的药物组合物。
背景技术
运动过量很容易造成肌肉损伤，主要是由于运动导致了肌肉疲劳所致，过量运动后临床可表现为不同程度的疼痛及功能障碍，主要是由于局部肌肉的过度负荷或反复用力导致肌肉疲劳；此外，许多慢性消耗性疾病也中很常见肌肉疲劳，这与疾病影响了肌肉的能量代谢及肌营养障碍有关。有关肌肉疲劳及损伤的机制，目前学术界提出了肌细胞能量代谢紊乱学说、细胞内钙稳态失调学说、自由基和脂质过氧化学说、机械损伤学说以及炎性损伤学说等不同假说，尚没有公认的结论。肌细胞能量代谢紊乱学说认为肌肉收缩过程中，肌细胞内能量物质耗竭与代谢产物的堆积，对肌纤维的功能和整个肌肉的工作能力均产生影响，是运动导致骨骼肌微损伤发生的一个重要原因。机体的一切生命活动都伴随着能量代谢，无论是运动性还是静力性引起的肌肉收缩舒张的运动，其实质都是能量代谢的过程。糖、脂肪、蛋白质等分解代谢过程中产生的大部分能量并不能直接被细胞利用，而是用于合成含有高能磷酸键的高能磷酸化合物。三磷酸腺苷（ATP）是体内最主要的高能磷酸化合物，磷酸肌酸（PCr）是合成ATP必不可少的关键物质，其中ATP是肌细胞收缩时唯一可以直接利用的供能物质。肌细胞中可提供能量合成ATP的代谢系统包括：磷酸原供能系统、糖酵解供能系统以及有氧代谢供能系统。研究表明，高能磷酸化合物作为磷酸原供能系统中的关键物质，在肌肉损伤的发生过程中具有重要作用，骨骼肌收缩时，ATP提供肌纤维的收缩蛋白-肌动蛋白和肌球蛋白在连接和分离的过程中要消耗能量，肌肉活动的横桥周期将贮存于ATP的化学能转化为机械能，使横桥从肌动蛋白上解离，完成肌肉的收缩。若ATP耗竭，附着于肌动蛋白的横桥不能解离，肌肉变得僵硬而不能舒张。如果肌肉长期处于收缩状态，导致ATP分解速率大于合成速率，那么ADP、AMP、Pi和乳酸等代谢产物在体内大量堆积，导致pH值下降，肌肉酶活性及电解质浓度亦发生改变。研究发现，ADP和Pi从肌动蛋白-肌球蛋白复合物（AM）的解离是不同步的，所产生的作用也不相同。Pi的解离与AM复合物从低力结合态到高力结合态的转变相偶联，其解离触发储存在肌球蛋白横桥中的能量释放，使横桥滑动，而肌球蛋白的头部和肌动蛋白的脱离首先需要ADP的解离，之后ATP与肌球蛋白分子结合，横桥断开，随后ATP被位于肌球蛋白头部的ATP酶分解。有科学工作者采用骨骼肌静力性负荷损伤动物模型研究亦表明，骨骼肌细胞内乳酸等代谢产物堆积，与骨骼肌静力性损伤密切相关，可能是引起骨骼肌静力性损伤的重要因素。目前普遍认为，肌肉疲劳同时也伴有肌细胞内H+浓度升高，与肌张力下降之间有很高的相关性，是导致肌肉疲劳的另一个重要因素。研究认为，H+抑制肌张力产生的作用机制可能为：作为ATP水解产物，H+释放是在横桥循环中完成的，当H+浓度升高时，可能使其释放过程逆转；同时，H+ 浓度升高，竞争性地与Tnc上低亲和力的Ca2+专一位置（Ⅱ位）结合，抑制了Ⅱ位与Ca2+的结合，使Ca2+敏感性降低，从而引发肌肉疲劳和损伤。另一方面，肌肉持续收缩导致局部血管受压，血供减少，细胞缺氧，而线粒体对缺氧最为敏感，因此首先出现损伤，使能量生成进一步减少，长期影响可导致肌肉结构的损伤。关于肌肉疲劳/损伤肌与糖原的关系，糖原主要贮存在肝脏和肌肉中，人体中的糖原80%都存在于骨骼肌中。肌糖原对肌细胞的活动有着极为重要的作用，是肌肉处于长时间收缩状态时的主要供能物质。研究发现，肌肉疲劳及损伤的发生多伴随着肌糖原的耗竭。在从中等到大负荷运动的过程中，肌糖原不仅是主要的能量来源，而且是必不可少的底物，因此它的大量减少将引起肌肉疲劳及损伤。肌浆网Ca2+-ATP酶活力的降低与肌浆网Ca2+释放的减少密切相关，肌糖原耗竭可影响兴奋-收缩耦联过程，降低Ca2+-ATP酶活力，减少肌浆网Ca2+释放，从而使肌原纤维蛋白的功能受损。有人通过核磁共振（NMR）对骨骼肌的研究，验证了一个新的能量代谢模型——糖原短路，可认为分为3个阶段：①在骨骼肌收缩的起初15ms左右，磷酸肌酸（PCr）分解提供能量重新合成 ATP；②在骨骼肌收缩的15-100ms间，由糖原分解提供能量重新合成PCr，PCr再分解合成ATP；③在收缩期间或休息时间，糖原合成酶利用生成乳酸有氧氧化提供的能量重新合成肌糖原。此模型的关键在于，先是快速地释放能量，以供应骨骼肌快速收缩所需；然后调控糖原分解的磷酸化酶可以快速地被Ca2+和磷酸化的级联反应所激活，产生的6-磷酸葡萄糖沿糖酵解途径产生ATP，以供肌肉收缩所需；收缩期间，持续的糖原分解伴随着糖原的再合成，糖原合成酶利用乳酸的有氧氧化产生的能量，将血液中的葡萄糖又重新合成糖原补充肌糖原库。糖原短路满足了肌肉快速收缩时能量的快速供应，乳酸的生成缓解了能量快速需求和能量慢速供应之间的矛盾，从而使乳酸解离后肌细胞内H+浓度升高，造成不同程度的肌肉疲劳及损伤[郭鑫,肌肉疲劳及肌肉损伤机制研究综述,中华中医药杂志 2016,31(7):2720]。这些研究均提示了肌糖原的耗竭是肌肉疲劳、损伤及萎缩的主要原因。
果糖是葡萄糖同分异构体，为最甜的单糖。食用果糖不易导致高血糖及龋齿,果糖在体内可不依赖于胰岛素合成肝糖原和肌糖原，肝脏和肌肉富含果糖激酶，果糖激酶是催化果糖被机体利用关键酶，肝脏和肌肉是也是果糖代谢的主要器官。果糖是机体合成多种营养及能量物质的重要原料，同时服用等量的果糖与葡萄糖，果糖在血液的浓度显著低于葡萄糖，其代谢速度也显著慢于葡萄糖，其最终转化为甘油酸盐和葡萄糖。此外，果糖可被高效转化为“三羧酸循环中间产物”如苹果酸、柠檬酸、酮戊二酸；或氨基酸，如谷氨酸、谷氨酰胺、丙氨酸；及尿素循环代谢物，如鸟氨酸或瓜氨酸。此外，果糖的三碳代谢物“甘油醛”是三羧酸循环中间产物及甘油磷酸的主要来源。我们的研究发现，适量给以果糖时，可以使由d-半乳糖导致的衰老小鼠的腓肠肌萎缩及重量减轻的症状得到缓解，提示了果糖对肌肉萎缩及重量减轻有一定的保护作用，这些作用与果糖进入肌肉后直接合成肌糖原，促进肌肉蛋白质的合成有关。当果糖摄入量高于一定的量时，有报道会导致尿酸增高，脂代谢异常，肥胖，并与心血管疾病，糖尿病有一定的关系，因此，使果糖大量应用防治肌肉萎缩存在一定的问题。
橘红对催化黄嘌呤和次黄嘌呤的氧化生成尿酸的黄嘌呤氧化酶有抑制作用，可以使尿酸浓度降低，可以防治果糖大量应用导致的尿酸浓度过高，预防高尿酸血症，从而避免了可能出现的痛风。橘红是由芸香科植物化洲柚或柚未成熟或近成熟的果实外果皮干燥而成，具有化痰止咳、理气健胃的功效，主治风寒咳嗽、痰多气逆、实积暖气等证。化橘红外果皮主要含挥发油、黄酮类及多糖等成分。挥发油以单萜类及其衍生物为主；黄酮类成分主要为柚皮苷、少量的野漆树苷、新橙皮苷、枳属苷等；还含有多糖类物质等；此外，还有香豆素类化合物异欧前胡素和佛手内酯。化橘红中黄酮类化合物是化橘红的主要有效成分，其中最主要是柚皮苷和野漆树苷，二者含量之和占化橘红黄酮类物质总量的84％以上。因此，在现有的质量控制标准中，把总黄酮含量、柚皮苷含量作为化橘红的关键质量控制指标。动物实验证明橘红具有显著的化痰止咳，抗炎、抗氧化、免疫调节、防治糖尿病心肌功能损伤等作用。橘红的多糖成分具有显著的止咳化痰作用，对慢性支气管炎和肺气肿均有良好的治疗效果。有学者采用二甲苯耳廓肿胀致炎法、小鼠浓氨水引咳法、小鼠气管段酚红排泌法分别观察化州橘红多糖对小鼠的消炎、止咳和化痰功效，研究发现化州橘红多糖对二甲苯引起的小鼠耳廓肿胀有不同程度的抑制作用，其中化州橘红多糖低、中、高剂量组的肿胀抑制率分别为24．93％、34.84％和48.72％，阿司匹林阳性对照组的肿胀抑制率为52.83％；化州橘红多糖能明显延长浓氨水刺激引起的小鼠的咳嗽潜伏期及减少2 min内的咳嗽次数，其中化州橘红多糖高剂量组的效果好于磷酸苯丙哌林片阳性对照组；化痰试验显示化州橘红多糖中、高剂量组与空白对照组之间存在显著性差异 (P<0.01)，低剂量组差异不明显，即化州橘红多糖能够增加小鼠气管段酚红的排泌量，说明化州橘红多糖具有较好的消炎、止咳及化痰作用。关于橘红的抗炎、抗氧化及免疫调节作用已经有较多的文献报道，近年有研究者观察到橘红对心肌损伤有很好的保护作用，研究者注意到糖尿病心肌病是糖尿病的最常见并发症，与慢性充血性心功能衰竭的发生发展密切相关，患者的致残致死率高，橘红提取物对实验性2型糖尿病心肌病大鼠的心肌结构功能损伤有防治作用，其机制可能与抑制心肌p38M APK信号通路有关。橘红含有的柚皮苷具有多种生物学活性，包括抗过敏反应，抗氧化，降血脂，对杂环胺类物质等致突变性的抑制作用，抗癌，对胃溃疡的防治，对金黄色葡萄球菌、沙门氏菌、志贺氏菌、埃氏大肠杆菌及某些真菌的抑制作用，抗炎，对某些毒物的拮抗作用，降血脂，降血胆固醇，解痉，镇痛，改善微循环和软骨组织细胞功能作用，降低毛细血管通透性和骨关节病变率作用，促进一些药物在人体内的吸收和代谢，促进成骨细胞增殖和分化、抑癌等多种药理活性。近年有研究提示柚皮苷有预防骨质疏松症的作用，柚皮苷能增加成骨细胞标志蛋白（如骨钙蛋白、骨桥蛋白、护骨素及骨形成蛋白-2）的表达，同时还能抑制与破骨细胞相关的基因的蛋白表达，抑制破骨细胞的增殖活性，从而使破骨细胞的破骨作用下降，起到延缓骨质疏松的作用。我们探讨橘红与果糖联合应用对衰老动物模型的研究中，发现果糖与橘红口服液对D-半乳糖小鼠衰老动物模型不但有明显改善骨生物力学的作用，还有明显地增加骨骼肌肌肉的重量的作用，这些意想不到的实验结果提示，果糖与橘红组成的组合物，可以成为强壮肌肉增强运动能力的保健食品或者药品。
发明内容
本项目申请人提出，由果糖与橘红可以组成一组强骨壮肌增强运动能力的保健食品和药品，由于运动过量，损伤，疾病或者衰老都可以导致肌肉疲劳，肌肉丢失，最终导致肌肉萎缩，无力；其原因与胰岛素分泌缺陷或其生物作用受损有关，血液中的葡萄糖不能被肌肉细胞组织利用，得不到足够的能量补充，因此，肌肉组织由于缺乏能量而发生病变或者萎缩老化，补充果糖可以使肌肉获得生命必须的能量补充，果糖可以不通过胰岛素途径直接进入肌肉，直接转化为肌糖原，及时补充了肌肉组织细胞因能量缺乏导致的代谢障碍，同时，补充橘红，可以促进骨骼的胶原和蛋白质的合成，同时，也可以肌肉组织的修复及蛋白质合成，使肌肉更加强壮，更加有力，两者合用，共同发挥了强骨壮肌增强运动能力的作用。
本发明提出一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品组合物，其具体产品的的配方及生产工艺如下。
1、果糖橘红颗粒：该产品的配方及生产工艺是：配方：橘红100kg，结晶果糖12kg；生产工艺是把橘红粉碎为粗粉，用75%乙醇加热回流提取两次，每次1.5小时，趁热过滤，滤液回收乙醇并浓缩至相对密度1.30~1.32（60~65℃），减压干燥，粉碎成细粉；滤渣再加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，滤液浓缩至相对密度1.30~1.32（60~65℃）的清膏，减压干燥，粉碎成细粉，把两种细粉与结晶果糖混合均匀，通过喷雾干燥法制成颗粒，包装，即得。
2、果糖橘红含片：该产品的配方及生产工艺是：配方：橘红100kg，甘草33 kg，结晶果糖12kg；生产工艺是把橘红、甘草粉碎为粗粉，用70%乙醇加热回流提取两次，每次1.5小时，趁热过滤，滤液回收乙醇并浓缩至相对密度1.30~1.32（60~65℃），减压干燥；滤渣再加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，滤液浓缩至相对密度1.30~1.32（60~65℃）的清膏，减压干燥，与醇提物合并，加入结晶果糖，粉碎成细粉，过筛，均匀，压片，包装，即得。用橘红，甘草，按3:1比例水提，最后浓缩到橘红50%，果糖为12%。
3、果糖橘红口服液：该产品的配方及生产工艺是：配方：橘红50kg，甘草16kg，结晶果糖6kg；生产工艺是把橘红、甘草粉碎为粗粉，加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，减压浓缩，加入结晶果糖，搅拌使溶解，加水调整到含果糖量为6%浓度，分装100ml/瓶，灭菌，即得。
4、果糖橘红袋泡茶：该产品的配方及生产工艺是：配方：橘红50~100kg，结晶果糖6~12kg；茶叶6~10kg 生产工艺是把橘红，茶叶粉碎为粗粉，加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，滤液浓缩至相对密度1.30~1.32（60~65℃）的清膏，减压干燥，加入结晶果糖，粉碎成细粉，过筛，均匀，分装，包装，即得。
5、果糖橘红饮料：该产品的配方及生产工艺是：配方：橘红50~100kg，甘草20~30kg，结晶果糖6~12kg；生产工艺是把橘红，甘草粉碎为粗粉，加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，减压浓缩，加入结晶果糖，搅拌使溶解，加水调整到合适浓度，分装250ml/瓶，灭菌，即得。
具体实施方式：
以上产品的配方及生产工艺也是是本发明的具体实施例，但是本发明的保护范围并不限于这些实施例，凡是不背离本发明构思的改变或等同替代均包括在本发明的保护范围之内。
实施例一
为了评价橘红果糖制剂骨生物力学与肌肉的影响，我们采用D-半乳糖建立一种伴有肌肉损伤的衰老小鼠模型，按照果糖橘红口服液配方及工艺制备为实验用药，实验是调整液体中果糖浓度为12%，橘红按生药计算的浓度为50%，小鼠用量按0.1ml/10g灌胃给药；具体的实验方法是选择清洁级白色昆明小鼠100只,雄性，体重20g-30g,在普通级动物饲养房内饲养,动物于实验前适应环境1周,普通颗粒饲料喂养,饮清洁自来水,每笼10只。实验分为（1）正常对照组：小鼠按每10克体重0.1ml灌胃给予生理盐水。（2） D-半乳糖模型组：每天背部皮下注射2.5%D-半乳糖0.1ml/10g，连续4周，造成衰老模型，并按0.1ml/10g灌胃给予生理盐水。（3）D-半乳糖模型+阳性对照组：罗钙全，0.25ug 配成33.3ml的水溶液，按0.1ml/10g灌胃给药。（4）D-半乳糖模型+12%果糖：小鼠按0.1ml/10g灌胃给予12%果糖；（5）D-半乳糖模型+果糖橘红口服液组：实验时，小鼠按0.1ml/10g灌胃给果糖橘红口服液（含果糖为12%，橘红50%）。小鼠于适应性喂养一周后开始给药，连续8周。实验过程中每天观察小鼠进食、饮水、活动情况等变化并记录，7天称体重1次，并按体重变化调整给药量。实验结束后，取左侧股骨，去除股骨周围的肌肉和肌腱，采用Lloyd LR5K Plus 骨生物力学检测系统检测和分析标本的生物力学指标，实验采用三点弯曲法，步骤如下：将大鼠左侧股骨置于试验机上，用1mm直径的压头，加载速度为2mm/min，跨距L为20mm，股骨加压至发生骨折，这可提供屈服点和骨折参数的测量，仪器将及时记录出每个时刻点的载荷（F）和桡度(d)变化值，绘制出载荷-位移曲线，然后读取最大载荷、断裂载荷和弹性载荷，并计算刚度。实验同时取腓肠肌，称重，并切片，进行HE染色、Masson染色，IPP软件统计肌纤维直径、数量。实验小鼠股骨的生物力学性能检测结果见表1，腓肠肌的重量及与体重的比例见表2。
表1：果糖橘红口服液对小鼠骨生物力学的影响
注：*：与对照组比较P<0.05；#：与模型组比较P<0.05。
从表1结果可见，模型组与对照组比较，小鼠的骨生物力学性能没有明显的改变，但是，在应用阳性对照药罗盖全，可使小鼠的骨生物力学性能得到全面的提升，而应用果糖橘红口服液也可以使小鼠的股骨的弹性载荷的力学性能得到明显提升，统计学有显著性意义，弹性载荷反映了骨在弹性范围所能承受的最大变形长度，果糖橘红口服液明显增加了骨的弹性载荷性能，说明了该产品可以增加骨的胶原蛋白的合成，使骨的弹性载荷明显性能提升，具有明显的强骨功能，即增加骨的力学性能。实验还观察到单独应用果糖，对骨力学性能没有明显影响。
表2：果糖橘红口服液对肌肉重量的影响
| 组别 | 体重 | 肌重 | 体肌比（%） |
| 正常对照 | 45.3±2.58 | 0.179±0.013 | 0.397±0.033 |
| 模型组 | 44.8±2.72 | 0.173±0.017 | 0.385±0.022 |
| 模型+阳性对照 | 47.0±5.02 | 0.180±0.024 | 0.384±0.044 |
| 模型+12%果糖 | 44.8±2.49 | 0.196±.017**## | 0.438±0.030**## |
| 模型+果糖橘红 | 46.6±2.57 | 0.194±0.013**## | 0.417±0.020**## |
注：**：与对照组比较P<0.01；##：与模型组比较P<0.01。
从表2结果可见，应用D-半乳糖后，小鼠的腓肠肌有减轻的趋势，但没有统计学意义，给以12%的果糖之后，服用果糖的小鼠腓肠肌重量明显增加，与模型组对照，差异非常显著（P<0.01），与正常对照组比较，差异也非常显著（P<0.01），说明了应用D-半乳糖造模后的小鼠，灌胃服用12%的果糖一个月之后，可以明显增加腓肠肌的重量，而服用果糖橘红口服液的小鼠，与模型组对照，差异非常显著（P<0.01），与正常对照组比较，差异也非常显著（P<0.01），说明了应用D-半乳糖造模后的小鼠，灌胃服用果糖橘红口服液一个月之后，也可以明显增加腓肠肌的重量，似比单独应用果糖更重，但没有统计学差异。由于橘红可以增加骨的生物力学性能，特别是增加骨的胶原蛋白的合成，使骨的弹性载荷明显性能提升，运动时不容易发生骨折，两种物质合用，对强骨壮肌增强运动能力将会具有意想不到的特殊功效。
Claims (6)
1.一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺。
2.如权利要求1所述的一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺，其特征是制备果糖橘红颗粒的配方及生产工艺是：配方：橘红100kg，结晶果糖12kg； 生产工艺是把橘红粉碎为粗粉，用75%乙醇加热回流提取两次，每次1.5小时，趁热过滤，滤液回收乙醇并浓缩至相对密度1.30~1.32（60~65℃），减压干燥，粉碎成细粉；滤渣再加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，滤液浓缩至相对密度1.30~1.32（60~65℃）的清膏，减压干燥，粉碎成细粉，把两种细粉与结晶果糖混合均匀，通过喷雾干燥法制成颗粒，包装，即得。
3.如权利要求1所述的一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺，其特征是制备果糖橘红含片的配方及生产工艺是： 配方：橘红100kg，甘草33 kg，结晶果糖12kg； 生产工艺是把橘红、甘草粉碎为粗粉，用70%乙醇加热回流提取两次，每次1.5小时，趁热过滤，滤液回收乙醇并浓缩至相对密度1.30~1.32（60~65℃），减压干燥；滤渣再加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，滤液浓缩至相对密度1.30~1.32（60~65℃）的清膏，减压干燥，与醇提物合并，加入结晶果糖，粉碎成细粉，过筛，均匀，压片，包装，即得。
4.如权利要求1所述的一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺，其特征是制备果糖橘红口服液的配方及生产工艺是： 配方：橘红50kg，甘草16kg，结晶果糖6kg； 生产工艺是把橘红、甘草粉碎为粗粉，加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，减压浓缩，加入结晶果糖，搅拌使溶解，加水调整到含果糖量为6%浓度，分装100ml/瓶，灭菌，即得。
5.如权利要求1所述的一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺，其特征是制备果糖橘红袋泡茶的配方及生产工艺是： 配方：橘红50~100kg，结晶果糖6~12kg；茶叶6~10kg 生产工艺是把橘红，茶叶粉碎为粗粉，加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，滤液浓缩至相对密度1.30~1.32（60~65℃）的清膏，减压干燥，加入结晶果糖，粉碎成细粉，过筛，均匀，分装，包装，即得。
6.如权利要求1所述的一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺，其特征是制备果糖橘红饮料的配方及生产工艺是： 配方：橘红50~100kg，甘草20~30kg，结晶果糖6~12kg； 生产工艺是把橘红，甘草粉碎为粗粉，加水蒸煮两次，第一次2小时，第二次1.5小时，合并蒸液，过滤，减压浓缩，加入结晶果糖，搅拌使溶解，加水调整到合适浓度，分装250ml/瓶，灭菌，即得。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810590903.8A CN108714171A (zh) | 2018-06-09 | 2018-06-09 | 一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810590903.8A CN108714171A (zh) | 2018-06-09 | 2018-06-09 | 一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108714171A true CN108714171A (zh) | 2018-10-30 |
Family
ID=63912049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810590903.8A Pending CN108714171A (zh) | 2018-06-09 | 2018-06-09 | 一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108714171A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110754558A (zh) * | 2018-12-22 | 2020-02-07 | 广东永青生物科技有限公司 | 一组以结晶果糖为主要能源原料制备的果糖能量咀嚼片 |
| CN110934883A (zh) * | 2019-12-14 | 2020-03-31 | 湛江广医医药科技开发有限公司 | 一组改善男性骨质疏松预防骨折的柚皮苷制剂 |
| CN113412897A (zh) * | 2021-06-19 | 2021-09-21 | 庞志杰 | 一种橘红饮品及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103566165A (zh) * | 2012-08-09 | 2014-02-12 | 福建建东药业有限公司 | 一种橘红片的工艺 |
-
2018
- 2018-06-09 CN CN201810590903.8A patent/CN108714171A/zh active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103566165A (zh) * | 2012-08-09 | 2014-02-12 | 福建建东药业有限公司 | 一种橘红片的工艺 |
Non-Patent Citations (1)
| Title |
|---|
| 顾民杰等: "果糖对耐久性运动能力的影响", 《中国运动医学杂志》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110754558A (zh) * | 2018-12-22 | 2020-02-07 | 广东永青生物科技有限公司 | 一组以结晶果糖为主要能源原料制备的果糖能量咀嚼片 |
| CN110934883A (zh) * | 2019-12-14 | 2020-03-31 | 湛江广医医药科技开发有限公司 | 一组改善男性骨质疏松预防骨折的柚皮苷制剂 |
| CN113412897A (zh) * | 2021-06-19 | 2021-09-21 | 庞志杰 | 一种橘红饮品及其制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8173181B2 (en) | Method and composition for improved anabolism | |
| CN109364194A (zh) | 维持骨骼健康及治疗骨关节炎和关节的骨关节病的组合物 | |
| JP2007536250A (ja) | 骨格筋におけるクレアチンの取り込みを増大するための栄養組成物 | |
| CN108714171A (zh) | 一组由果糖和橘红组成的强骨壮肌增强运动能力的保健食品及药品的配方及生产工艺 | |
| WO2003053166A1 (en) | Food or pet food composition containing plant extract for bone health | |
| KR101806474B1 (ko) | 갈색거저리 추출물을 함유하는 골질환의 개선, 예방 또는 치료용 조성물 | |
| US20140242200A1 (en) | Water-soluble extracts of artemisia dracunculus (tarragon) for improvement of glucose metabolism | |
| CN107242552A (zh) | 具有缓解体力疲劳及增强免疫力功能的保健食品组合物 | |
| CN107455625A (zh) | 一种具有抗疲劳减肥功能的植物营养素饮料及其制备工艺 | |
| US20110123654A1 (en) | Synergistic enhancement of cellular ergogenic nutrient uptake, like creatine or carnitine, with tarragon | |
| US8613959B2 (en) | Dietary supplements containing extracts of Nelumbo and processes of using same | |
| CN101343317A (zh) | 脑肽及其制备方法及其用途 | |
| KR102444911B1 (ko) | 산나물 추출물을 유효성분으로 하는 근육관련 질환 예방 또는 치료, 근기능 개선 또는 운동수행능력 개선용 조성물 | |
| CN108703992A (zh) | 一组由果糖和黄芪组成的强骨壮肌防治肌肉萎缩的保健食品及药品的配方及生产工艺 | |
| KR102301757B1 (ko) | 스트레스로 인한 기억력 감퇴 억제 및 학습 능력 향상을 위한 천연 혼합 조성물 | |
| AU2011300376B2 (en) | Ingredients derived from Sphaeranthus indicus | |
| RU2408383C1 (ru) | Композиция с противоопухолевой и адаптогенной активностью (варианты) и лекарственный препарат на ее основе (варианты) | |
| US20220313750A1 (en) | Composition containing enterococcus faecalis as active ingredient for preventing or treating obesity or metabolic syndromes induced thereby | |
| JP6273440B2 (ja) | Ｇｌｐ−１産生促進剤、ｄｐｐｉｖ阻害剤及びグルコース吸収阻害剤 | |
| JP2008074734A (ja) | インスリン抵抗性改善剤 | |
| US20130280367A1 (en) | Method and Composition for Increasing Energy and Focus | |
| CN107205460A (zh) | 含有红花籽提取物、乳香提取物及黄芩提取物作为有效成分的骨长度增长促进及骨密度增加用食品组合物 | |
| KR101336068B1 (ko) | 한약재의 추출물과 분획물을 포함하는 항당뇨 조성물 | |
| US10010571B2 (en) | Nutritional supplement for the enhancement of muscle irisin and enhancement of brown fat, metabolic rate, and weight loss, and methods of use thereof | |
| KR0137897B1 (ko) | 두충엽을 주원료로 함유한 건강식품 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20181030 |